Citius Oncology has secured up to $36.5 million in a mix of debt and equity, providing critical funding to commercialize its recently approved lymphoma treatment in a bullish market for biotech financing.
Back
Citius Oncology secures $36.5 million to accelerate cancer drug launch
Citius Oncology is moving to accelerate the U.S. launch of its cancer therapy LYMPHIR® after securing up to $36.5 million in fresh capital, signaling strong investor confidence in the targeted oncology market. The financing, announced May 5, provides Citius with a significant cash runway to support the rollout of its treatment for cutaneous T-cell lymphoma (CTCL).
"This Credit Facility strengthens our ability to continue to execute on the LYMPHIR launch, aligning capital access with commercial performance," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology, in a statement. He added it "underscores the confidence that a global investment firm like Avenue Capital has in our commercial trajectory."
The financing package includes a senior secured term loan of up to $25 million from Avenue Capital Group and approximately $11.5 million in gross proceeds from a concurrent warrant exercise. The warrant exercise was conducted with a single healthcare-focused institutional investor at a reduced price of $0.90 per share.
The capital injection is crucial for Citius (Nasdaq: CTOR) to penetrate the estimated $400 million U.S. market for CTCL. The deal structure, which combines debt with equity, is designed to fund commercial operations including sales force expansion and market access initiatives while managing shareholder dilution as the company scales.
Financing Details
The debt facility with Avenue Capital provides an initial $10 million tranche at closing, with two additional tranches of up to an aggregate of $15 million available upon achieving certain revenue milestones. In parallel, the immediate exercise of outstanding warrants provides non-dilutive cash flow to support near-term commercial efforts. H.C. Wainwright & Co. acted as the exclusive placement agent for the financings.
"Citius Oncology has a differentiated, FDA-approved therapy with a targeted commercial opportunity," said Chad Norman, Senior Portfolio Manager of Avenue Capital Group. "We are excited to support the Citius team as they execute on their commercialization strategy."
Bull Market for Oncology Funding
The Citius deal lands amid a fertile funding environment for late-stage oncology companies. On the same day, Cellectar Biosciences (NASDAQ: CLRB) announced an oversubscribed financing of up to $140 million, led by Nantahala Capital, to advance its treatment for Waldenström macroglobulinemia. The strong investor appetite, with participation from funds like Balyasny Asset Management and Janus Henderson Investors in the Cellectar deal, shows that specialized biotechs with approved or near-approval assets can attract significant capital.
This trend occurs within a broader context of high-value transactions across the healthcare sector, including major hospital mergers like the recently announced combination of WakeMed and Atrium Health [1].
LYMPHIR®, a recombinant fusion protein that targets IL-2 receptors on cancer cells, was approved by the FDA in December 2025 for adult patients with relapsed or refractory Stage I-III CTCL. The new funding is expected to provide Citius with a cash runway to support a full-scale commercial launch, aiming to establish LYMPHIR® as a key therapy for a patient population with limited treatment options.
This article is for informational purposes only and does not constitute investment advice.
[1] Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization[2] WakeMed CEO says years of talks led to Atrium deal: ‘We’re the smallest health system of the competitive world now in North Carolina’[3] Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million[4] 15 physician deals in 40 days
